Annual Report 2022

CORPORATE CALENDAR OF 2022 3 The United Laboratories International Holdings Limited Annual Report 2022 September October • The Amoxicillin Sodium (a sterile active substance of antibiotics) and other products of Zhuhai United Laboratories were awarded a certificate of GMP compliance by Spanish Agency of Medicines and Medical Products (AEMPS). • The sterile active substances and other products of The United Animal Healthcare (Inner Mongolia) passed the new GMP for veterinary drugs. • The United Laboratories was awarded the “Most Valuable Listed Company” for 2022 by Sina Finance in HK and US stock markets. • The United Laboratories’ Semaglutide Injection was approved for clinical trials. • TUL01101 Ointment (specification: 0.5%, 1% and 2%), a class I new drug for atopic dermatitis was approved for clinical trials. • The registration application for clinical trials of TUL12101 Eye Drops, a class I new drug for dry eye syndrome was accepted. • The United Laboratories’ Sodium Hyaluronate Eye Drops (specification: 0.1% (0.4 ml: 0.4 mg)) were approved for marketing and deemed to pass the quality and efficacy consistency evaluation of generic drugs. November December • The United Laboratories was selected as one of CHEO (China Health Ecology Organization)’s “Top 100 Enterprises with Comprehensive Competitiveness in the Pharmaceutical Industry for 2022”. • The United Laboratories’ Amoxicillin won the Antibiotic Brand Gold Award of the “Health Industry Brand List for 2022” of CHEO (China Health Ecology Organization). • The United Laboratories’ Sodium Hyaluronate Eye Drops (specification: 0.3% (0.4 ml: 1.2 mg)) were approved for marketing and deemed to pass the quality and efficacy consistency evaluation of generic drugs. • Zhuhai United Laboratories was ranked 22th of the “2021 Top 100 Pharmaceutical Enterprises in China”.